Psychology Today | 29.07.2026 04:46
Earlier this year, I wrote about one of psychiatry's most unusual drug-development stories: a psychedelic compound first identified in the defensive secretions of the Sonoran Desert toad that has now entered the realm of randomized clinical trials for severe depression. The field has advanced dramatically beyond the early period when the compound was known primarily through recreational use and colorful names such as Bufo, Sapito, "the toad," and even "the Joe Rogan psychedelic." Today's scientific story, however, has surprisingly little to do with the toad itself.
